Objectives: the aim of this study was to estimate the population under Vitamin-K antagonists (VKA) in the region of Limousin (France), and to assess the treatment quality and the level of knowledge of the patients.
Methods: a transversal study permitted to identify all the patients under VKA under the French general health care coverage. During 6 months, a cohort of 370 patients had been followed. Major data measured were: the number of INR, the duration within the therapeutic range, the duration in the hazardous zone (INR >4.5), the level of patients' education and the knowledge on the treatment's indication by biologists. Data were collected through the French general health care database as well as questionnaires sent to general practitioners, biologists and patients.
Results: one percent of the entire population was under VKA. The mean number of INR performed during 6 months was 6.6, and 36.5% of patients had less than one biological control monthly. The mean duration passed within the therapeutic range was at 54%. The hazardous zone was reached by 22% of the patients. The level of education of the patients was poor in one half of the patients. The indication of the treatment was known in 6% of patients' biologists.
Conclusion: these results reflect the limits of application of recommendations. Facing to this evidence, it is necessary to optimize the management and follow-up of these treatments, especially through the development of public health charters with biologists, education with patients, or even anticoagulant clinics.
Download full-text PDF |
Source |
---|
Orthop Surg
January 2025
Department of Orthopedic Surgery, St. Vincent's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea.
Objective: Central sensitization (CS) is associated with quality of life (QOL) after total knee arthroplasty (TKA). However, how CS changes after TKA and whether these changes have clinical relevance remain unclear. Therefore, this study was conducted to identify changes in CS after TKA and to assess the clinical significance of these changes.
View Article and Find Full Text PDFIUBMB Life
January 2025
Precision Medicine Laboratory, School of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China.
Triple-negative breast cancer (TNBC) remains a significant global health challenge, emphasizing the need for precise identification of patients with specific therapeutic targets and those at high risk of metastasis. This study aimed to identify novel therapeutic targets for personalized treatment of TNBC patients by elucidating their roles in cell cycle regulation. Using weighted gene co-expression network analysis (WGCNA), we identified 83 hub genes by integrating gene expression profiles with clinical pathological grades.
View Article and Find Full Text PDFHead Neck
January 2025
Departement de Pathologie, Centre Hospitalo-Universitaire Montpellier, Montpellier, France.
Background: The detection rate of oncogenic human papillomaviruses (HPVs) in sinonasal squamous cell carcinomas (SNSCCs) varies among studies. The mutational landscape of SNSCCs remains poorly investigated.
Methods: We investigated the prevalence and prognostic significance of HPV infections based on p16 protein expression, HPV-DNA detection, and E6/E7 mRNA expression using immunohistochemistry, polymerase chain reaction, and in situ hybridization, respectively.
Foot Ankle Spec
January 2025
Department of Trauma Surgery, Northwest Clinics, Alkmaar, the Netherlands.
Surgical site infections (SSIs) are the most common complication after surgery for ankle fractures. This retrospective study aimed to determine the pathogens cultured in SSI and their antimicrobial susceptibility patterns to provide a recommendation for empirical therapy. Patients who underwent surgical treatment for an ankle fracture were included.
View Article and Find Full Text PDFCancer Cytopathol
February 2025
Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Background: Major mutations (e.g., KRAS, GNAS, TP53, SMAD4) in pancreatic cyst fluid (PCF) are useful for classifying and risk stratifying certain cyst types, particularly in cases with nondiagnostic cytology.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!